Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 4/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 4/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 4/20 | 0.39 |
| ▸ | FFAR3 | O14843 | 3/20 | 0.39 |
| ▸ | CES2 | O00748 | 1/20 | 0.36 |
| ▸ | CES1 | P23141 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.31 |
| ▸ | CTSD | P07339 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10581622 | 0.87 | CES1 (0.41) | CES2CES1ALDH1A1 | |
| SCHEMBL11306443 | 0.81 | — | — | |
| SCHEMBL5193264 | 0.80 | HDAC1 (0.37) | HDAC3HDAC1HDAC2HDAC8FFAR3 | |
| SCHEMBL4778152 | 0.77 | — | — | |
| SCHEMBL2050674 | 0.75 | CES2 (0.43) | HDAC3HDAC1HDAC2HDAC8FFAR3 | |
| SCHEMBL104701 | 0.75 | — | — | |
| SCHEMBL21662481 | 0.73 | — | — | |
| SCHEMBL15796734 | 0.71 | — | — | |
| SCHEMBL13000044 | 0.71 | — | — | |
| SCHEMBL5613195 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8298513-B2 | Hexatriene-β-carbonyl compound | OSAKA UNIVERSITY (JP) | 2012-10-30 | — | — | US | disclosed |
| US-20100008857-A1 | NOVEL HEXATRIENE-BETA-CARBONYL COMPOUND | OSAKA UNIVERSITY (JP) | 2010-01-14 | — | — | US | disclosed |
| US-4987132-A | PLATELET ACTIVATING FACTOR ANTAGONISTS | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 1991-01-22 | — | — | US | disclosed |
| EP-0309841-A2 | Amino acid derivatives | MERCK PATENT GmbH (DE) | 1989-04-05 | — | — | EP | disclosed |
| EP-0148883-A1 | ALLOPURINOL PRODRUGS. | GEA AS (DK) | 1985-07-24 | — | — | EP | disclosed |
| WO-1985000368-A1 | ALLOPURINOL PRODRUGS | A/S GEA (DK) | 1985-01-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100008857-A1 | NOVEL HEXATRIENE-BETA-CARBONYL COMPOUND | CBR1, CBR3, DCXR | HDAC3 1031/4885HDAC1 1457/4885HDAC2 1399/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.